Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
Solriamfetol (Sunosi, Jazz Pharmaceuticals) to treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea was approved on March 20, 2019.
The FDA has approved semaglutide (Ozempic, Novo Nordisk) for the reduction of major adverse cardiovascular (CV) events in patients with type 2 diabetes and established CV disease.
Pharmacists can play an integral role in managing patients with psoriasis through medication therapies and lifestyle modifications.
Shingles vaccination recommended by CDC and ADCES.
Antipsychotics were not associated with an increased risk of morbidity and mortality in patients with schizophrenia in a new study.
Here are the top drugs expected to be approved this year.
Individuals with a history of heart disease may be at an increased risk of developing kidney failure.
As the price of insulin has skyrocketed, patients with diabetes are struggling to pay for their medication.
Overall cancer death rates declined by 29% over a 26-year time period, with the largest single-year drop on record reported from 2016 to 2017.